EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

5563 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 BONE DENSITY DECREASED 3091
1 RENAL INJURY 2565
2 SKELETAL INJURY 2396
3 TOOTH LOSS 1710
4 CHRONIC KIDNEY DISEASE 1660
5 TOOTH INJURY 1651
6 RENAL FAILURE 1325
7 BONE LOSS 1293
8 MULTIPLE FRACTURES 1254
9 OSTEONECROSIS 1252
See all common reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOOTH INJURY 1651 0.5099
1 SKELETAL INJURY 2396 0.2529
2 BONE DEMINERALISATION 76 0.1704
3 BONE DENSITY DECREASED 3091 0.1170
4 DEGENERATIVE BONE DISEASE 26 0.1102
5 BONE LOSS 1293 0.1051
6 TOOTH LOSS 1710 0.1037
7 RENAL INJURY 2565 0.0947
8 MULTIPLE FRACTURES 1254 0.0934
9 COELIAC ARTERY ANEURYSM 1 0.0714
See all enriched reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE